Ammine/Amine Platinum IV Dicarboxylates: A Novel Class of Complexes Which Circumvent Intrinsic Cisplatin Resistance

  • K. R. Harrap
  • B. A. Murrer
  • C. Giandomenico
  • S. E. Morgan
  • L. R. Kelland
  • M. Jones
  • P. M. Goddard
  • J. Schurig

Abstract

Since its introduction into clinical practice some 20 years ago, cisplatin has made a major impact on the response rates of several human malignancies, notably testicular and ovarian cancers. Nonetheless, this drug does have limitations: its severe side-effects, its poor activity against some common tumours (e.g. breast and non small cell lung cancers, Loehrer and Einhorn, 1984) and its inability to confer lasting remissions in responding tumour types (especially ovary) due to the emergence of drug resistance.

Keywords

Antitumour Activity Platinum Complex Flameless Atomic Absorption Human Ovarian Carcinoma Cell Line Flameless Atomic Absorption Spectrometry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andrews P.A. and Howell S.B., 1990, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 36Google Scholar
  2. Burchenal J.H., Irani G., Kern K., Lokys L and Turkevich J., 1980, 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Rec. Res. Cancer Res. 74: 146CrossRefGoogle Scholar
  3. Calvert A.H., Harland S.J., Newell D.R., Siddik Z.H., Jones A.C., NcElwain T.J., Raju S., Wiltshaw E., Smith I.E., Baker J.M., Peckham M.J. and Harrap K.R., 1982, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother. Pharmacol. 9: 140PubMedCrossRefGoogle Scholar
  4. de Graeff A., Slebos R.J.C. and Rodenhuis S., 1988, Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother. Pharmacol. 22: 325PubMedCrossRefGoogle Scholar
  5. Eisenhauer E., Swerton K., Sturgeon J., Fine S., O’Reilly S. and Canetta R., 1990, Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature, in: “Carboplatin: Current Perspectives and Future Directions”, P. Bunn, R. Canetta, R. Ozols and M. Rozencweig, eds., W.B. Saunders Company, Philadelphia, p. 133.Google Scholar
  6. Evans B.D., Raju K.S., Calvert A.H., Harland S.J. and Wiltshaw E., 1983, JM8 (cis-diammine-1,1-cyclobutane dicarboxylate platinum II), a new platinum analogue active in the treatment of advanced ovarian carcinoma. Cancer Treat. Rep. 67: 997PubMedGoogle Scholar
  7. Gore M., Fryatt I., Wiltshaw E., Dawson T., Robinson B. and Calvert A., 1989, Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer 60: 767PubMedCrossRefGoogle Scholar
  8. Harrap K.R., 1985, Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12 (Suppl. A): 21.Google Scholar
  9. Harrap K.R., Jones M., Goddard P.M., Orr R.M. and Siddik Z.H., 1988, Drug resistance as a focus for new drug design, in: “Mechanisms of Drug Resistance in Neoplastic Cells — Bristol-Myers Cancer Symposia, Volume 9”, P.V. Woolley and K.D. Tew, eds., Academic Press, New York, p. 307.Google Scholar
  10. Harrap K.R., Jones M., Siracky J., Pollard LA. and Kelland L.R., 1990, The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Annals of Oncology 1: 65PubMedGoogle Scholar
  11. Harrap K.R., Kelland L.R., Jones M., Goddard P.M., Orr R.M., Morgan S.E., Murrer B.A., Abrams M.J. and Giandomenico C.M., 1991, Platinum coordination complexes which circumvent cisplatin resistance. Adv. Enzyme Regln. 31: in press.Google Scholar
  12. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P. and Harrap K.R., 1989, Biological properties often human ovarian carcinoma cell lines: calibration in vitro against 4 platinum complexes. Br. J. Cancer 59: 527PubMedCrossRefGoogle Scholar
  13. Loehrer P. and Einhorn L, 1984, Cisplatin. Ann. Int. Med. 100: 704PubMedCrossRefGoogle Scholar
  14. Morrison, S.D., 1983, In vivo estimation of size of experimental tumours. J. Natl. Cancer Inst. 71: 407PubMedGoogle Scholar
  15. Orr R.M., O’Neill C.F., Murrer B.A., Nicolson M.C. and Harrap K.R., 1989, Evaluation of novel platinum II and platinum IV ammine/amine complexes using L1210 sublines resistance to cisplatin or tetraplatin. Proc. Am. Assoc. Cancer Res. 30: 509Google Scholar
  16. Siddik Z.H., Boxall F.E. and Harrap K.R., 1987, Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilised in hyamine hydroxide. Analyt. Biochem. 163: 21PubMedCrossRefGoogle Scholar
  17. Skehan P., Storreng R., Scudiero N., Monks A., McMahon J., Vistica D., Warren J., Bokesh H., Kinney S. and Boyd M., 1989, Evaluation of colorimetric and biomass stains for assaying in vitro drug effects upon human tumour cells. Proc. Am. Assoc. Cancer Res. 30: 612Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • K. R. Harrap
    • 1
  • B. A. Murrer
    • 2
  • C. Giandomenico
    • 2
  • S. E. Morgan
    • 1
  • L. R. Kelland
    • 1
  • M. Jones
    • 1
  • P. M. Goddard
    • 1
  • J. Schurig
    • 3
  1. 1.The Institute of Cancer ResearchSurreyUK
  2. 2.Johnson Matthey Technology CentreReadingUK
  3. 3.Bristol-Myers Squibb CompanyConnecticutUSA

Personalised recommendations